Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 Vaccines and the Skin
The Landscape of Cutaneous Vaccine Reactions Worldwide

Qisi Sun, MD\textsuperscript{a,1}, Ramie Fathy, AB\textsuperscript{b,1}, Devon E. McMahon, MD\textsuperscript{c}, Esther E. Freeman, MD, PhD\textsuperscript{c,*}

INTRODUCTION
As of April 22, 2021, the novel coronavirus disease 2019 (COVID-19) has sickened more than 142 million people and taken more than 3 million lives worldwide.\textsuperscript{1} Although restrictions such as physical distancing are crucial to containment, these measures are only temporary solutions. One silver lining amid this crisis is that the tragedy has become a catalyst. Scientists around the globe have raced to develop a long-term solution to impede viral transmission. On March 13, 2020, just 63 days after the genetic sequence of severe acute respiratory syndrome novel coronavirus 2 (SARS-CoV-2) was published, researchers began testing the first doses of a human COVID-19 vaccine.\textsuperscript{2} By December 2, 2020, the United Kingdom became the first country to approve of and distribute the Pfizer-BioNTech BNT162b2 vaccine.\textsuperscript{3} The United States followed suit days later, with the Food and Drug Administration (FDA) issuing Emergency Use Authorizations for both the Pfizer-BioNTech and Moderna vaccines. Since then, several COVID-19 vaccines have been authorized and approved for distribution around the globe, with many more in the pipeline. Of significance to dermatologists are the increasing reports of cutaneous reactions associated with these vaccines. The American Academy of Dermatology and the International League of Dermatologic Societies COVID-19 Registry began collecting such cases in late December 2020. The cases submitted ranged from delayed large local reactions to pityriasis rosea-like eruptions and reactivation of herpes simplex and varicella zoster.\textsuperscript{4} Mass vaccination is key to achieving herd

\textsuperscript{a} Department of Dermatology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA; \textsuperscript{b} Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA; \textsuperscript{c} Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
\textsuperscript{1} Co-first authors.
\textsuperscript{*} Corresponding author.
E-mail address: efreeman@mgh.harvard.edu

Dermatol Clin 39 (2021) 653–673
https://doi.org/10.1016/j.det.2021.05.016
0733-8635/21/© 2021 Elsevier Inc. All rights reserved.
immunity and ending the pandemic. Therefore, it is critical that providers are aware of and understand the cutaneous side effects among the approved vaccines to better educate patients and provide proper counseling.

In this article, we evaluate the landscape of dermatologic side effects from COVID-19 vaccines worldwide. We first summarize the latest skin reactions reported in clinical trial data following the administration of 11 different approved COVID-19 vaccines, before describing additional skin findings in reports outside of clinical trials.

**CUTANEOUS MANIFESTATIONS OF COVID-19 VACCINATION IN CLINICAL TRIALS**

As of April 15, 2021, 13 vaccines have achieved regulatory authorization and approval: Pfizer-BioNTech’s BNT162b2, Moderna’s mRNA-1273, Oxford-AstraZeneca’s AZD1222, Gamaleya’s Sputnik V, Johnson & Johnson’s Janssen’s Ad26.COV2.S, Sinovac’s CoronaVac, Sinopharm’s BBIBP-CorV, The Vector Institute’s EpiVacCorona, CanSino’s Convidecia, Bharat’s Covaxin, Sinopharm’s WIBP-CorV, Chumakov’s CoviVac and Anhui Zhifei Longcom’s ZF2001 (Table 1).5 Of these vaccines, 11 have published trial data (Table 2).

The most common adverse cutaneous reactions noted were local injection site reactions such as erythema, swelling, tenderness, pain, induration, and pruritus within 7 days after injection. Mild to moderate injection site pain was the most prevalent event among all 11 COVID-19 vaccine trials, with up to 88% of participants experiencing pain that typically resolved within 24 to 48 hours after onset. Erythema, swelling, induration, and itch were less common, and reported in up to 20%, 15%, 25%, and 35% of participants, respectively (see Table 2). An emerging trend is the higher incidence of these local injection site reactions in the younger population compared with participants age 60 years and older.6-8

Delayed large local reactions, with a typical onset of 8 days or more after vaccination and consisting of erythema, induration, and tenderness, were specifically reported in Moderna’s phase III trial.6 After the first dose, 244 participants (0.8%) in the vaccinated cohort developed mild, delayed injection reactions that resolved over the course of 4 to 5 days.5 After the second dose, 68 participants (0.2%) developed delayed large local reactions.5 There was no mention, however, of whether those who had reactions after the first dose experienced a recurrence after the second dose.

Although infrequent, a series of other dermatologic manifestations with varying severity have been reported. Less than 0.2% of Moderna’s vaccinated cohort developed rashes, including allergic, atopic, and contact dermatitis; eczema; exfoliative rash; hypersensitivity reactions; injection site urticaria; papular urticaria; and vesicular rash, among others (see Table 2).6 Although specific characteristics such as timing and duration were not reported, none of these skin findings were labeled as severe.6 Similarly, acneiform and allergic dermatitis, alopecia, petechial rash and eczema were seen in less than 0.1% of Sputnik V’s vaccinated participants.9 One participant developed an unspecified rash in the BBIBP-CorV vaccine trial and another developed a mild unspecified rash in the Covaxin trial.8,10 Vaccine-related buccal ulceration and oral herpess were also noted in the Convidecia vaccine cohort.11

Three cases of serious cutaneous reactions were observed among these 11 vaccines. One participant in the CoronaVac trial developed a severe, acute hypersensitivity reaction with urticaria 48 hours after the first dose.12 The rash resolved within 3 days after the administration of chlorphenamine and dexamethasone, and a similar reaction was not observed after the second dose.12 Among the 11 recipients of the ZF2001 vaccine who developed unspecified rashes, 1 case was labeled as severe (grade 3 or higher).13 The AZD1222 trial reported 1 case of severe cellulitis in addition to one case each of vaccine-induced psoriasis, rosacea, vitiligo, and Raynaud phenomenon.14

**CUTANEOUS MANIFESTATIONS OF COVID-19 VACCINATION IN REAL-WORLD SETTINGS**

Dermatologic reactions to COVID-19 vaccines may be largely uncommon among clinical trial participants, but as we enter global mass vaccination, these adverse events will increase and new cutaneous reactions will emerge. In fact, numerous observational reports and case series of COVID-19 vaccine-related dermatoses have been published recently. An increased awareness of these manifestations can help dermatologists to identify potential risks, engage in anticipatory guidance, and initiate appropriate management. Here, we present an overview of the latest nontrial literature on reactive dermatoses to COVID-19 vaccines.

**Delayed Large Local Reactions**

A delayed large local reaction, defined as the onset of an erythematous and edematous patch at the injection site at least 4 days or more after vaccine administration, was the most commonly noted adverse cutaneous event in nontrial literature.4 Across all 6 observational studies, 350 participants experienced at least one episode of delayed large local reaction (Table 3). Of these
### Table 1
Characteristics of 13 authorized/approved COVID-19 vaccines as of April 21, 2021

| Vaccine Name(s)                  | Manufacturer(s)                                                                                                                                                                                                 | Type                                      | Country of Origin          | Trial Phase with Published Data | Trial Time Frame                        | Age Group Tested |
|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|----------------------------|----------------------------------|----------------------------------------|------------------|
| BNT162b2, Comirnaty              | Pfizer-BioNTech, Fosun Pharma                                                                                                                                                                                  | mRNA                                      | US, Germany                 | III                              | 7/27/2020—11/14/2020                  | 16+              |
| mRNA-1273                        | Moderna, National Institute of Allergy and Infectious Diseases                                                                                                                                                  | mRNA                                      | US                         | III                              | 7/27/2020—10/23/2020                 | 18+              |
| AZD1222, ChAdOx1 nCoV-19         | Oxford-AstraZeneca                                                                                                                                                                                              | Adenovirus                                | UK                         | I/II                             | 4/23/2020—11/4/2020                  | 18+              |
| Sputnik V, Gam-COVID-Vac         | Gamaleya Research Institute; Health Ministry of the Russian Federation                                                                                                                                           | Recombinant adenovirus (rAd26, rAd5)     | Russia                     | III                              | 9/7/2020—11/24/2020                  | 18+              |
| Ad26.COV2.S, JNJ-78436735        | Johnson & Johnson’s Janssen Biotech                                                                                                                                                                            | Nonreplicating viral vector              | The Netherlands, US        | I/IIa                            | 7/22/2020—11/7/2020                  | 18–55, 65+       |
| CoronaVac                        | Sinovac Biotech                                                                                                                                                                                                  | Inactivated (formalin with alum adjuvant) | China                      | I/II                             | Phase I: 4/16/2020—4/25/2020 Phase II: 5/3/2020—5/5/2020 | 18–59            |
| BBIBP-CorV                       | China National Pharmaceutical Group (Sinopharm); Beijing Institute of Biological Products                                                                                                                                 | Inactivated                               | China                      | I/IIa                            | 5/18/2020—7/30/2020                  | 18–59            |
| EpiVacCorona                     | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology                                                                                                                      | Peptide                                   | Russia                     | I/IIa                            | 7/27/2020—Present                    | 18–60            |
| Convidicea, Ad5-nCoV             | CanSino Biologics                                                                                                                                                                                                | Recombinant (adenovirus type 5 vector)   | China                      | III                              | 4/11/2020—4/16/2020                  | 18+              |

(continued on next page)
| Vaccine Name(s) | Manufacturer(s)                                | Type         | Country of Origin | Trial Phase with Published Data | Trial Time Frame (Phase I) | Age Group Tested |
|----------------|-----------------------------------------------|--------------|-------------------|--------------------------------|---------------------------|------------------|
| Covaxin, BBV152 | Bharat Biotech; Indian Council of Medical Research | Inactivated   | India             | I/II                           | 9/5/2020—9/12/2020       | 12–65            |
| WIBP-CorV      | China National Pharmaceutical Group (Sinopharm); Wuhan Institute of Biological Products | Inactivated   | China             | I/II                           | 4/12/2020—5/2/2020       | 18–59            |
| CoviVac        | Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products | Inactivated   | Russia            | I/II <sup>a</sup>              | N/A                      | N/A              |
| ZF2001         | Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology of the Chinese Academy of Sciences | Recombinant   | China, Uzbekistan | I/II                           | Phase I: 6/22/2020—7/3/2020  
Phase II: 7/12/2020—7/17/2020 | 18–59            |

<sup>a</sup> No data published yet as of April 22, 2021.
| Vaccine name(s) | Erythema | Swelling | Tenderness | Pain | Induration | Pruritus | Other Skin Findings | Serious Cutaneous Reactions |
|----------------|----------|----------|------------|------|------------|---------|---------------------|---------------------------|
| **BNT162b2, Comirnaty** | | | | | | | | |
| **Dose 1:** | 16–55 y: 5%>55 y: 5% | | | | | | | None |
| **Dose 2:** | 16–55 y: 6%>55 y: 7% | | | | | | | None |
| **mRNA-1273** | 2.8% | 6.1% | 10.2% | | 83.7% | | | None |
| **Dose 1:** | | | | | | | | |
| **Dose 2:** | | | | | | | | |
| **AZD1222, ChAdOx1 nCoV-19** | | | | | | | | |
| **Group 1a, 1b, 2a, 2b:** | | | | | | | | |
| **Without paracetamol prophylaxis:** | 3% | 4% | 83% | | 67% | | | One case each of psoriasis, rosacea, vitiligo and Raynaud phenomenon (<0.1%) |
| **With paracetamol prophylaxis:** | 2% | 2% | 77% | | 50% | | | One case of severe cellulitis |
| **Group 1a, 1b, 2a, 2b:** | | | | | | | | |
| **Without paracetamol prophylaxis:** | 7% | 3% | 0% | | 12% | | | |
| **With paracetamol prophylaxis:** | | | | | | | | |

(continued on next page)
| Vaccine name(s) | Erythema  | Swelling | Tenderness | Pain | Induration | Pruritus | Other Skin Findings | Serious Cutaneous Reactions |
|----------------|-----------|----------|------------|------|------------|---------|---------------------|-----------------------------|
|                | Group 3   | Group 3  | Group 3    | Group 3 | Group 3    | Group 3 |                     |                             |
|                | None      | None     | Dose 1: 50%| None  | None       | Dose 1: 10%|                     |                             |
|                |           |          | Dose 2: 50%| None  |            | Dose 2: 10%|                     |                             |
| Sputnik V,     | N/A       | N/A      | N/A        | N/A   | N/A        | N/A     | Acneiform dermatitis, | None                        |
| Gam-COVID-Vac  |           |          |            |       |            |         | allergic rash, alopecia, |                             |
|                |           |          |            |       |            |         | indeterminate rash, petechial rash, and eczema (<0.1%) |                             |
| Ad26.COVID2.S, | 7.3%      | 5.3%     | N/A        | 48.6% | N/A        | N/A     | None                |                             |
| JNJ-78436735   | 0/14 schedule: | 0/14 schedule: | 0/14 schedule: | 0/14 schedule: | 0/14 schedule: | 0/14 schedule: | One case of acute hypersensitivity with urticaria |                             |
|                | Dose 1:    | Dose 1:  | Dose 1:    | Dose 1: | Dose 1:    | Dose 1: | 48 h after dose 1 (6 µg group) |                             |
| CoronaVac      | 3 µg group: | 3 µg group: | 3 µg group: | 3 µg group: | 3 µg group: | 3 µg group: |                             |                             |
|                | 0.8%       | 0.8%     | 9.2%       | 0.8%  | 6 µg group: | 6 µg group: |                             |                             |
|                | None       | None     | Dose 2:    | 0.8%  | Dose 2:    | 0.8%   |                             |                             |
|                | 3 µg group: | 3 µg group: | 3 µg group: | 3 µg group: | 6 µg group: | 6 µg group: |                             |                             |
|                | 0.8%       | 0.8%     | 13.3%      | 0.8%  | 0/28 schedule: | 0/28 schedule: |                             |                             |
|                | None       | None     | 11.8%      | 0/28 schedule: | None       | None |                             |                             |
|                | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: |                             |                             |
|                | 1.7%       | 2.5%     | 2.6%       | 0.9%  | 6 µg group: | 5.9%   |                             |                             |
|                | 0/28 schedule: | 0/28 schedule: | 0/28 schedule: | 0/28 schedule: | None       | None |                             |                             |
|                | Dose 1:    | Dose 1:  | Dose 1:    | Dose 1: | Dose 1:    | Dose 1: |                             |                             |
|                | 3 µg group: | 3 µg group: | 3 µg group: | 3 µg group: | 3 µg group: | 3 µg group: |                             |                             |
|                | 0.8%       | 0.8%     | 7.5%       | 0.9%  | 0/28 schedule: | 0/28 schedule: |                             |                             |
|                | None       | None     | Dose 2:    | 2.6%  | None       | None |                             |                             |
|                | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: | 5.9%       | None |                             |                             |
|                | 0.8%       | 0.8%     | 10%        | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | None       | None     | Dose 2:    | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: | 5.9%       | None |                             |                             |
|                | 0.8%       | 0.8%     | 10%        | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | None       | None     | Dose 2:    | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: | 5.9%       | None |                             |                             |
|                | 0.8%       | 0.8%     | 10%        | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | None       | None     | Dose 2:    | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: | 5.9%       | None |                             |                             |
|                | 0.8%       | 0.8%     | 10%        | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | None       | None     | Dose 2:    | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: | 5.9%       | None |                             |                             |
|                | 0.8%       | 0.8%     | 10%        | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | None       | None     | Dose 2:    | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: | 5.9%       | None |                             |                             |
|                | 0.8%       | 0.8%     | 10%        | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | None       | None     | Dose 2:    | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
|                | 6 µg group: | 6 µg group: | 6 µg group: | 6 µg group: | 5.9%       | None |                             |                             |
|                | 0.8%       | 0.8%     | 10%        | 2.6%  | 6 µg group: | 5.9%   |                             |                             |
| Vaccine | Phase | Dose 1 | Dose 2 | Other Adverse Events |
|---------|-------|--------|--------|----------------------|
| BBIBP-CorV | 1% | 2% | N/A | 16% | N/A | 2% | Unspecified rash in 1 participant (<1%) | None |
| Convidica, Ad5-nCoV | Low dose: 2% | High dose: 1% | Low dose: 4% | High dose: 4% | Low dose: 57% | High dose: 2% | Low dose: 6% | High dose: 2% | One case of buccal ulceration within 14 d | None |
| Covaxin, BBV152 | Dose 1: 3μg group: 1% | 6μg group: 1% | Dose 2: None | N/A | N/A | Dose 1: 3μg group: 3% | 6μg group: 3% | Dose 2: 3μg group: 4% | 6μg group: 2% | One case of mild unspecified rash after dose 2 (3 μg group) | None |
| WIBP-CorV | Phase I (0, 28, 56-d group): | Low dose: None | Medium dose: None | High dose: None | Phase I (0, 28, 56-d group): | Low dose: 20.8% | Medium dose: 4.2% | High dose: 25% | Phase II 0 and 14-d group: Medium dose: 2.4% | 0 and 21-d group: Medium dose: 14.3% | N/A | None |
| | Phase II 0 and 14-d group: | Medium dose: None | 0 and 21-d group: None | Medium dose: None | Phase II 0 and 14-d group: | Medium dose: None | 0 and 21-d group: None | Medium dose: None | Medium dose: 1.2% | N/A | None |
| Vaccine name(s) | Erythema | Swelling | Tenderness | Pain | Induration | Pruritus | Other Skin Findings | Serious Cutaneous Reactions |
|----------------|----------|----------|------------|------|------------|---------|---------------------|---------------------------|
| ZF2001         | Phase I  | Phase I  | N/A        | Phase I | Phase I | Phase I | One case of unspecified rash in the phase I trial (50 µg group) | One case of unspecified grade ≥3 rash (50 µg group) |
| Two-dose group:| 25 µg:   | 25 µg:   | 20%        | 25 µg: | 20%       | 20%     | Three cases of unspecified rash in the phase II trial, 2-dose schedule, 25 µg group | Four cases of unspecified rash in the phase II trial, 2-dose schedule, 50 µg group |
| 25 µg group:   | 8%       | 25 µg:   | 8%         | 25 µg: | 3%        | 6%      | 2 cases of unspecified rash in phase II trial, three-dose schedule, 25 µg group | One case of unspecified rash in phase II trial, three-dose schedule, 50 µg group |
| 50 µg group:   | 4%       | 50 µg:   | 3%         | 50 µg: | 5%        | 9%      |  |
| 50 µg group:   | 5%       | 50 µg:   | 5%         | 50 µg: | 5%        | 9%      |  |
| Three-dose group: | 6% | Three-dose group: |  |
| 25 µg group:   | 16%      | 25 µg:   | 12%        | 25 µg: | 9%        | 19%     |  |
| 50 µg group:   | 14%      | 50 µg:   | 12%        | 50 µg: | 7%        | 17%     |  |
| One case of unspecified rash in the phase I trial, 50 µg group | | | | | | | | |
| Article Reference | Study Design | Study Size | Study Period | Vaccine Name(s) | Cutaneous Reactions | Dose Number | Time to Onset after Vaccination | Time to Resolution | Intervention |
|-------------------|-------------|------------|--------------|-----------------|--------------------|-------------|---------------------------------|-------------------|--------------|
| Delayed large local reactions |
| Fernandez-Nieto et al., 2021 | Retrospective study at a tertiary referral hospital in Spain | 4775 | 1/11/2021–2/12/2021 | BNT162b2/Comirnaty | 103 participants with delayed large local reactions | Dose 1: 49/103 (47.6%) Dose 2: 54/103 (52.4%) | N/A | <8 h: 23/103 (22.3%) 8–24 h: 27/103 (26.2%) 48–72 h: 38/103 (36.9%) >72 h: 14/103 (13.6%) | N/A |
| Blumenthal et al., 2021 | Case series | 12 | N/A | mRNA-1273 | 12 participants with delayed large local reactions after dose 1 3 participants with similarly severe reactions, 3 participants with less severe reactions after dose 2 | Dose 1: 12/12 (100%) Dose 2: 6/12 (50%) | N/A | Dose 1: 1–3 d (median 2 d) Dose 2: 2–11 d after onset (median, 6 d) | Ice, antihistamines, glucocorticoids (topical, oral or both), antibiotics |
| McMahon et al., 2021 | Retrospective review of AAD/ILDS registry of vaccine-related cutaneous reactions | 414 | 12/24/2020–2/14/2021 | BNT162b2/Comirnaty mRNA-1273 | 12 reports of delayed large local reactions mRNA-1273 206 reports of delayed large local reactions | BNT162b2/Comirnaty: Dose 1: 5/34 (15%) Dose 2: 7/40 (18%) mRNA-1273 Dose 1: 175/267 (66%) Dose 2: 31/102 (30%) | BNT162b2/Comirnaty: N/A mRNA-1273: median 7 d after dose 1, median 3 d after dose 2 | BNT162b2/Comirnaty: N/A mRNA-1273: median 4 d after dose 1; median 3 d after dose 2 | Topical corticosteroids, oral antihistamines, pain relievers, antibiotics |

(continued on next page)
| Article Reference          | Study Design | Study Size | Study Period | Vaccine Name(s)          | Cutaneous Reactions                                                                 | Dose Number | Time to Onset after Vaccination | Time to Resolution | Intervention                                      |
|----------------------------|--------------|------------|--------------|--------------------------|-------------------------------------------------------------------------------------|-------------|---------------------------------|---------------------|---------------------------------------------------|
| Wei et al, 2021            | Case series  | 4          | N/A          | mRNA-1273                | Delayed large local reactions                                                       | Dose 1      | Case 1: 8 d                     | Case 1: N/A         | Case 1 and 2: topical corticosteroids, oral antihistamine Case 3 and 4: None |
| Ramos et al, 2021          | Case series  | 12         | N/A          | BNT162b2/Comirnaty mRNA-1273 | BNT162b2/Comirnaty: report of delayed large local reaction mRNA-1273 11 reports of delayed large local reactions | Dose 1      | 5–11 d (average 7 d)            | 3–8 d (average 5 d) | Topical corticosteroids, ice, oral antihistamines, pain relievers |
| Baeck et al., 2021         | Case report  | 1          | N/A          | BNT162b2/Comirnaty        | Delayed large local reaction                                                         | Dose 1 only | 6 d                             | 5 d                 | N/A                                               |
| Morbilliform rashes        |              |            |              |                          |                                                                                     |             |                                 |                     |                                                   |
| Jedlowski et al, 2021      | Case report  | 1          | N/A          | BNT162b2/Comirnaty        | Morbilliform rash on lower back                                                      | Dose 1 and dose 2: 48 h | 5–45 min                       | N/A                 | Intramuscular epinephrine                        |
| CDC COVID-19 Response Team and FDA 2021 | Case series  | 10         | 12/21/2020–1/10/2021 | mRNA-1273               | 4 cases of morbilliform rash                                                        | Dose 1      | 5–45 min                       | N/A                 | Intramuscular epinephrine                        |
| CDC COVID-19 Response Team and FDA 2021 | Case series  | 21         | 12/14/2020–12/23/2020 | BNT162b2/Comirnaty       | 7 cases of morbilliform rash                                                        | Dose 1      | 2–25 min                       | N/A                 | Intramuscular epinephrine                        |
| Ackerman et al., 2021 | Case report | 1 | N/A | BNT162b2/ Comirnaty | Maculopapular exanthema (30% body surface area) | Dose 1 (dose 2 avoided) | 3 h | >1 mo | Corticosteroids |
|----------------------|-------------|---|-----|---------------------|-----------------------------------------------|-------------------------|-----|------|----------------|
| Corbeddu et al., 2021 | Case series | 11 | N/A | BNT162b2/ Comirnaty | 3 cases of morbilliform rashes | Dose 2: 3/3 (100%) | Dose 2: 5 hours–3 days | 2–3 d | None |
| McMahon et al., 2021 | Retrospective review of AAD/ILDS registry of vaccine-related cutaneous reactions | 414 | 12/24/2020–2/14/2021 | BNT162b2/ Comirnaty | 9 reports of morbilliform rash mRNA-1273 | BNT162b2/ Comirnaty: reports of morbilliform rash mRNA-1273 18 reports of morbilliform rash | BNT162b2/ Comirnaty: Dose 1: 6/9 (67%) Dose 2: 3/9 (33%) mRNA-1273 Dose 1: 11/18 (61%) Dose 2: 7/18 (39%) | Dose 1: Median of 3 d Dose 2: Median of 2 d | Dose 1: Median of 4.5 d Dose 2: Median of 2.5 d | Topical corticosteroids, oral antihistamines, pain relievers, antibiotics |

**Urticaria**

| CDC COVID-19 Response Team and FDA, 2021 | Case series | 10 | 12/21/2020–1/10/2021 | mRNA-1273 | 1 case of urticaria | Dose 1 | 11 min | N/A | Intramuscular epinephrine |
| CDC COVID-19 Response Team and FDA, 2021 | Case series | 21 | 12/14/2020–12/23/2020 | BNT162b2/ Comirnaty | 10 cases of urticaria | Dose 1 | 5–54 min | N/A | Intramuscular epinephrine |
| John M. Kelso, 2021 | Case series | 4 | N/A | mRNA-1273 | 1 case of urticaria | Dose 1 (dose 2 refused) | 1 min | N/A | Diphenhyramine, IV epinephrine, diazepam |
| Corbeddu et al., 2021 | Case series | 11 | N/A | BNT162b2/ Comirnaty | 2 cases of urticaria | Dose 1: 2/2 (100%) | Dose 1: 1 hour–2 days | 2–3 d | None |
| Park et al., 2021 | Case report | 1 | N/A | BNT162b2/ Comirnaty | Urticaria with immediate anaphylaxis | Dose 1 only | 3 min | 2 d | Intramuscular epinephrine and diphenhydramine |

(continued on next page)
| Article Reference          | Study Design                                      | Study Size | Study Period       | Vaccine Name(s)         | Cutaneous Reactions | Dose Number | Time to Onset after Vaccination | Time to Resolution | Intervention                           |
|---------------------------|---------------------------------------------------|------------|--------------------|-------------------------|---------------------|-------------|----------------------------------|-------------------|----------------------------------------|
| McMahon et al, 2021       | Retrospective review of AAD/ILDS registry of vaccine-related cutaneous reactions | 414        | 12/24/2020–2/14/2021 | BNT162b2/Comirnaty     | 17 reports of urticaria mRNA-1273 23 reports of urticaria | Dose 1: 9/17 (53%) Dose 2: 8/17 (47%) | Dose 1: 9 cases after 24 h Dose 2: 1 case within 24 h, 7 cases after 24 h mRNA-1273 Dose 1: 13 cases after 24 h 3 cases of unknown timing Dose 2: 2 cases within 24 h, 5 cases after 24 h | Median 5 d          | Topical corticosteroids, oral antihistamines, pain relievers, antibiotics |
| Gambichler et al., 2021   | Case report                                       | 1          | N/A                | BNT162b2/Comirnaty     | Rowell's syndrome   | Dose 1: 1 d 1 | N/A                             |                   | Oral corticosteroids                   |
| McMahon et al, 2021       | Retrospective review of AAD/ILDS registry of vaccine-related cutaneous reactions | 414        | 12/24/2020–2/14/2021 | mRNA-1273             | 3 reports of EM     | mRNA-1273    | N/A                             | N/A               | N/A                                    |
| Study | Design | N/A | Vaccine | DIRs | Vaccine | DIRs |
|-------|--------|-----|---------|------|---------|------|
| Munavalli et al, 2021 | Case series | 2 | N/A | BNT162b2/Comirnaty mRNA-1273 | 1 | Report of DIR to hyaluronic acid dermal fillers |
| | | | | mRNA-1273 | | Report of DIR to hyaluronic acid dermal fillers |
| | | | | | | Dose 1: 1/2 (50%) mRNA-1273 |
| | | | | | | Dose 1: 1/2 (50%) mRNA-1273 |
| | | | | | | Initiation of lisinopril at 48 h, resolved after 24 h |
| | | | | | | Corticosteroids, antihistamines, acetaminophen, lisinopril |
| Munavalli et al, 2021 | Case series | 4 | N/A | BNT162b2/Comirnaty mRNA-1273 | 2 | Reports of DIRs to hyaluronic acid dermal fillers |
| | | | | mRNA-1273 | | Reports of DIRs to hyaluronic acid dermal fillers |
| | | | | | | Dose 1: 1/2 (50%) mRNA-1273 |
| | | | | | | Dose 1: 16/23 (70%) mRNA-1273 |
| | | | | | | Initiation of lisinopril at 72 h, resolved after 24 h mRNA-1273 |
| | | | | | | Initiation of lisinopril at 48 h, resolved after 72 h |
| | | | | | | Low-dose lisinopril |
| McMahon et al, 2021 | Retrospective review of AAD/ILDS registry of vaccine-related cutaneous reactions | 414 | 12/24/2020-2/14/2021 | BNT162b2/Comirnaty mRNA-1273 | 1 | Report of DIR to hyaluronic acid dermal fillers |
| | | | | mRNA-1273 | | Report of DIR to hyaluronic acid dermal fillers |
| | | | | | | Dose 1: 1/1 (100%) mRNA-1273 |
| | | | | | | Dose 1: 3/8 (38%) mRNA-1273 |
| | | | | | | Dose 2: 5/8 (63%) mRNA-1273 |
| Article Reference | Study Design | Study Size | Study Period | Vaccine Name(s) | Cutaneous Reactions | Dose Number | Time to Onset after Vaccination | Time to Resolution | Intervention |
|-------------------|--------------|------------|--------------|-----------------|--------------------|-------------|-------------------------------|-------------------|--------------|
| **Local injection site reactions** | | | | | | | | | |
| McMahon et al., 2021 | Retrospective review of AAD/ILDS registry of vaccine-related cutaneous reactions | 414 | 12/24/2020–2/14/2021 | BNT162b2/Comirnaty mRNA-1273 | 16 reports of local injection site reactions mRNA-1273 186 reports of local injection site reactions | BNT162b2/Comirnaty: Dose 1: 8/16 (50%) Dose 2: 8/16 (50%) mRNA-1273 Dose 1: 117/186 (63%) Dose 2: 69/186 (37%) | Dose 1: Median day 1 Dose 2: Median day 1 | Dose 1: Median days 4 Dose 2: Median days 3 | | |
| **Erythromelalgia** | | | | | | | | | |
| McMahon et al., 2021 | Retrospective review of AAD/ILDS registry of vaccine-related cutaneous reactions | 414 | 12/24/2020–2/14/2021 | BNT162b2/Comirnaty mRNA-1273 | 3 reports of erythromelalgias mRNA-1273 11 reports of erythromelalgias | BNT162b2/Comirnaty: Dose 1: 1/3 (33%) Dose 2: 2/3 (67%) mRNA-1273 Dose 1: 5/11 (45%) Dose 2: 6/11 (55%) | Dose 1: Median day 7 Dose 2: Median day 1 | Dose 1: Median days 5.5 Dose 2: Median days 3 | N/A |
| **Lichen planus** | | | | | | | | | |
| Hiltun et al., 2021 | Case report | 1 | N/A | BNT162b2/Comirnaty | Lichen planus flare | Dose 2 | 48 h | N/A | Topical corticosteroids |
| **Varicella zoster** | | | | | | | | | |
| Bostan et al., 2021 | Case report | 1 | N/A | N/A | Varicella zoster flare | N/A | 5 d | 1 wk | Oral valacyclovir |
| Authors          | Type          | Start Date | End Date | Vaccine/Regimen                                                                 | Dose 1 | Dose 2 | Topical Corticosteroids |
|------------------|---------------|------------|----------|---------------------------------------------------------------------------------|--------|--------|-------------------------|
| McMahon et al.   | Retrospective | 12/24/2020 | 2/14/2021| BNT162b2/Comirnaty mRNA-1273                                                     | 2/5 (40%) | 4/5 (80%) |                          |
|                  | review of     |            |          |                                                                                  |        |        |                         |
|                  | AAD/ILDS      |            |          | registry of vaccine-related cutaneous reactions                                |        |        |                         |
|                  |               |            |          |                                                                                  |        |        |                         |
| Pityriasis rosea | Retrospective | 12/24/2020 | 2/14/2021| BNT162b2/Comirnaty mRNA-1273                                                     | 2/3 (67%) | 1/3 (33%) |                         |
|                  | review of     |            |          |                                                                                  |        |        |                         |
|                  | AAD/ILDS      |            |          | registry of vaccine-related cutaneous reactions                                |        |        |                         |
|                  |               |            |          |                                                                                  |        |        |                         |
| Busto-Leis et al.| Case series   | 2-14      |          |                                                                                  |        |        |                         |
|                  |               |            |          |                                                                                  |        |        |                         |
| Pernio/chilblains| Case report   | 1          |          |                                                                                  |        |        |                         |
|                  |               |            |          |                                                                                  |        |        |                         |
| Kha et al.       |               |            |          |                                                                                  |        |        | Topical corticosteroids |
|                  |               |            |          |                                                                                  |        |        |                         |

(continued on next page)
| Article Reference | Study Design | Study Size | Study Period | Vaccine Name(s) | Cutaneous Reactions | Dose Number | Time to Onset after Vaccination | Time to Resolution | Intervention |
|-------------------|--------------|------------|--------------|----------------|--------------------|-------------|-------------------------------|-------------------|--------------|
| McMahon et al, 2021 | Retrospective review of AAD/ILDS registry of vaccine-related cutaneous reactions | 414 | 12/24/2020–2/14/2021 | BNT162b2/Comirnaty mRNA-1273 | BNT162b2/Comirnaty: 5 reports of pernio/chilblains mRNA-1273 3 reports of pernio/chilblains | BNT162b2/Comirnaty: Dose 1: 3/5 (60%) Dose 2: 2/5 (40%) mRNA-1273 Dose 1: 3/3 (100%) | N/A | N/A | N/A |
| Lopez et al, 2021 | Case report | 1 | 1/2021 | BNT162b2 | Pernio/chilblains | Dose 2 | 3 d | >28 d | Clobetasol as needed, avoidance of cold exposure |
| McMahon et al, 2021 | Retrospective review of AAD/ILDS registry of vaccine-related cutaneous reactions | 414 | 12/24/2020–2/14/2021 | BNT162b2/Comirnaty mRNA-1273 | BNT162b2/Comirnaty: 1 report of petechiae mRNA-1273 3 reports of petechiae | BNT162b2/Comirnaty: Dose 1: 1/1 (100%) mRNA-1273 Dose 1: 1/3 (33%) Dose 2: 2/3 (67%) | N/A | N/A | N/A |
| Malayala et al, 2021 | Case report | 1 | 3/2021 | mRNA-1273 | Brown to red purpuric, nonblanchable rash | Dose 1 | 1 d | N/A | Monitoring of platelet, liver, renal function panels; antihypertensives |

**Abbreviations:** AAD, American Academy of Dermatology; CDC, Centers for Disease Control and Prevention; DIRs, delayed inflammatory reaction; EM, erythema multiforme; FDA, Food and Drug Administration; ILDS, International League of Dermatologic Societies; N/A, not applicable.

* Articles within each morphology group are organized in order of publication date.
350 individuals, 117 (33.4%) received the BNT162b2 vaccine and 233 (66.6%) received the mRNA-1273 vaccine (see Table 3).

Of note, female patients younger than 65 years of age consistently composed the majority of these delayed large local reactions, prompting the question of sex’s role in vaccine response. Notably, women also comprise an overwhelming majority (>70%) of the national and international health care workforce. Therefore, the observation may reflect a reporting bias, given that vaccination campaigns initially targeted health care professionals and that women may be more likely to visit their doctor. However, the cause is likely multifactorial, because biology is also at play. Women have stronger immune responses to foreign antigens than men, and decades of research have shown that although women exhibit a greater immune response to vaccines, they also experience more adverse events.

Although studies varied in their reporting of characteristics, most of the delayed large local reactions were mild and transient, with few recurrences after the second dose. All delayed large local reactions reported in the nontrial literature resolved within 11 days. In the study by McMahon and associates, only 11 participants developed reactions after both doses; all were mRNA-1273 vaccine recipients, and reactions after the second dose were frequently smaller in size with an earlier onset at a median of 2 days. Six of the 12 patients who received the mRNA-1273 vaccine in Blumenthal and colleagues had recurrent reactions that were of lesser severity than those after the first dose and also occurred at a median of 2 days. Likewise, of the 11 patients who received the mRNA-1273 vaccine in Ramos and Kelso, 4 developed similar local reactions after the second dose with an onset of 2 to 3 days after injection. Although most delayed large local reaction reports in nontrial literature occurred with the mRNA-1273 vaccine, these findings have also been observed with the BNT162b2 vaccine. Of the 103 patients reported on by Fernandez-Nieto and colleagues and who developed delayed local reactions after the first dose of BNT162b2, one-half experienced similar recurrent reactions after the second dose (onset not reported).

The morphology of these delayed large local reactions ranged from erythematous targetoid patches to large plaques. In 2 studies of mRNA-1273 vaccine recipients, lesion diameters ranged from 5.0 to 19.5 cm, with 7 of the 16 lesions labeled as grade 3 plaques (≥ 10 cm in diameter). Histology of these skin lesions revealed superficial and deep perivascular lymphocytic infiltrates with rare eosinophils and scattered mast cells, confirming a delayed type, T-cell–mediated hypersensitivity reaction. To date, no such findings have been reported with other non-mRNA COVID-19 vaccines and the exact etiology is still unknown. However, a delayed hypersensitivity reaction to polyethylene glycol, an allergen, may be one explanation because both BNT162b2 and mRNA-1273 vaccines contain this excipient.

Treatment has not been necessary; most reactions are mild and resolve spontaneously. Although some patients were treated with ice, antihistamines, pain relievers, and glucocorticoids (topical, oral, or both), others received no intervention. However, some patients received unnecessary antibiotics owing to concern for cellulitis or other infections, highlighting the need for more providers to recognize that these delayed large local reactions are benign and not a contraindication to the second dose.

**Morphilliform Rashes**

Morphilliform and maculopapular exanthems have been described in 43 participants across 3 observational studies (see Table 3). Of these 43 individuals, 21 (49%) received the BNT162b2 vaccine and 22 (51%) received the mRNA-1273 vaccine (see Table 3). Of these cases, 11 (4 associated with mRNA-1273; 7 associated with BNT162b2) had been submitted to the Vaccine Adverse Event Reporting System (VAERS) and labeled by the Centers for Disease Control and Prevention (CDC) as part of an anaphylaxis reaction.

Among the cases not characterized as anaphylaxis, most rashes occurred within 2 to 3 days after injection and resolved within 1 week. One recipient of the BNT162b2 vaccine developed a pruritic, maculopapular exanthem that persisted for more than 1 month. This patient, who had no significant past medical history or drug allergy, erupted in an erythematous rash over 30% of his body, including the face, trunk, upper extremities, and thighs, but sparing the oral and genital mucosa. Histologic examination revealed lymphocytic perivascular infiltrates, consistent with maculopapular toxidermia. Despite a lack of other systemic manifestations, the patient developed concomitant liver injury with slightly elevated aspartate transaminase and gamma-glutamyl transferase enzymes. Given the persistence of this exanthem, the patient was advised to avoid the second dose, and gradually the rash and elevated liver enzymes improved with corticosteroids. Another BNT162b2 vaccine recipient developed a pruritic morbilliform rash across his lower back 48 hours after injection; the rash self-resolved within
24 hours. Upon receiving the second dose, he developed a recurrent and more robust morbilliform eruption involving not only the lower back, but also the flanks, proximal extremities, and upper back. This rash also resolved within 24 hours without intervention.

Notably, morbilliform rashes have been reported in several cases of COVID-19 infection in both pediatric and adult populations.\textsuperscript{31–34} Histologic examinations of such cases have revealed spongiosis and mild dermal perivascular lymphocytic infiltrates, suggesting an immune-mediated etiology rather than a direct viral effect.\textsuperscript{35} Therefore, although the exact mechanism of COVID-19 vaccine-induced morbilliform rashes remains unknown, it is plausible that these cutaneous manifestations are also the result of an immune activation.

**Urticaria**

Urticaria is defined as wheals (hives) that typically resolve within 24 hours.\textsuperscript{36} It can either present as part of immediate hypersensitivity reactions, defined by the CDC as an onset within 4 hours after injection, or occur as similar reactions 4 hours after injection.\textsuperscript{37} This delineation is important to recognize because the former are potential contraindications to the second dose.

There are 55 cases of urticaria among the 6 observational reports in nontrial literature (see Table 3). Of these 55 individuals, 30 (55%) received the BNT162b2 vaccine and 25 (45%) received the mRNA-1273 vaccine (see Table 3). Of these cases, 11 (1 associated with mRNA-1273 and 10 associated with BNT162b2) had been submitted to the Vaccine Adverse Event Reporting System (VAERS) and labeled by the CDC as part of an anaphylaxis reaction.\textsuperscript{26} In contrast, in an analysis of 414 COVID-19 dermatology registry cases, none of the 40 urticaria reactions (17 associated with BNT162b2, 23 associated with mRNA-1273) were classified as an immediate hypersensitivity reaction.\textsuperscript{4}

One female patient in the report from Park and colleagues\textsuperscript{38} developed pruritic urticaria on her extremities and face within 3 minutes after administration of the BNT162b2 vaccine. However, history and test results demonstrated a baseline proclivity to allergic reactions and revealed a previously undiagnosed, underlying cholinergic urticaria.\textsuperscript{38} Given that she felt overheated while waiting in line for the dose, the anaphylaxis likely arose from heat-induced rather than vaccine-induced cholinergic urticaria. As such, she received the second dose in a cool, temperature-controlled room without incident.\textsuperscript{38} This case illustrates that categorically denying patients a second dose based solely on an anaphylactic reaction may erroneously prevent patients from reaping the benefits of immunization, because not all cases of anaphylaxis are directly vaccine related.

**Delayed Inflammatory Reactions to Dermal Hyaluronic Acid Fillers**

Hyaluronic acid fillers are increasingly resistant to biodegradation, resulting in longevity and more delayed inflammatory reactions (DIRs) to these implants. Among the known triggers of DIRs to fillers include viral illness, low-quality products, dental procedures, influenza vaccines, and, most recently, COVID-19 vaccines.\textsuperscript{4,39,40} To date, 15 cases have been reported across 3 observational studies. Of these reports, 11 (73%) are associated with the mRNA-1273 vaccine and 4 (27%) are associated with the BNT162b2 vaccine (see Table 3).

In many cases, DIRs occurred to fillers that had been injected more than 1 to 2 years before the COVID-19 vaccination.\textsuperscript{40} These reactions developed rapidly, often within 24 to 48 hours, and presented as swelling and inflammation focused around areas previously treated with fillers.\textsuperscript{39,40} Most cases were recalcitrant to antihistamines, hyaluronidase, and acetaminophen.\textsuperscript{39,40}

However, a novel mechanism for these reactions has been proposed, generating a potential pathogenesis-based treatment. Previous research revealed high expression of angiotensin-converting enzyme (ACE) 2 receptors in adipose tissue, where most fillers are injected.\textsuperscript{40} These receptors are targeted by the SARS-CoV-2 spike protein, and the resulting interaction in the skin releases a proinflammatory cascade, which may explain the DIRs to hyaluronic acid fillers seen in COVID-infection.\textsuperscript{41} By blocking the production of angiotensin II and thus reducing the substrate for ACE2, ACE inhibitors (ACE-I) in effect promote an anti-inflammatory response.\textsuperscript{39,40} Indeed, upon initiation with oral lisinopril, all DIRs resolved completely within 24 to 72 hours.\textsuperscript{39,40} Despite the success of ACE-Is in treating DIRs, further research on the proposed mechanism of action is warranted.

Important factors to consider when treating these reactions with ACE-Is include laboratory tests to assess for metabolic disturbances, especially if a patient is on medications that could interact with ACE-Is.\textsuperscript{39,40} Given that treatment of DIRs to hyaluronic acid fillers do not require a long course of ACE-Is, a brief discontinuation of concurrent drugs may suffice.

**Pernio and Chilblains**

Pernio-like lesions have been observed in COVID-19 infected individuals since the beginning of the
pandemic. Only recently have they also been associated with COVID-19 vaccines. Of the 10 cases described across 3 observation studies, 6 (60%) were associated with the BNT162b2 vaccine, and the rest were associated with the mRNA-1273 vaccine.

Pernio-like lesions tend to present as painless, erythematous, and violaceous papules and macules on the hands and feet, with some cases exacerbated by cold exposure. Histopathologic examinations of these vaccine-associated lesions reveal dense, perivascular lymphocytic infiltrates in the superficial to deep dermis, confirming the pernio diagnosis. With topical corticosteroids, these lesions can resolve in 1 week to 1 month.

The appearance of pernio lesions not just during COVID-19 infection, but also after vaccination suggests that the vaccines and SARS-CoV-2 activate a similar immune pathway. Although the mechanism remains unclear, these findings suggest that the pernio lesions seen in COVID-19 infection and after vaccination may be less directly related to viral effects.

### Other Reactions

Reports of other cutaneous reactions include early-onset local injection site reactions, erythromelalgia, erythema multiforme, lichen planus, varicella zoster and herpes simplex reactivation, pityriasis rosea-like reactions, petechial rash, and purpuric rash (see Table 3). Local injection site reactions occurring within 3 days of vaccination were the second most common skin manifestations observed in the analysis of 414 COVID-19 dermatology registry cases. Of the 202 cases of local injection site reactions, 186 (92%) were attributed to the mRNA-1273 vaccine. These findings were also widely reported in clinical trial data, but less frequently discussed in the nontrial literature, likely because this pattern of reactogenicity is commonly observed in other vaccines.

Some reactions, such as erythromelalgia, erythema multiforme, and pityriasis rosea, mimic known cutaneous manifestations of COVID-19 infection. Of the 14 reports of erythromelalgia, 11 (79%) were associated with the mRNA-1273 vaccine. Of the 4 cases of erythema multiforme, 3 (75%) were associated with the mRNA-1273 vaccine, and among the 6 reports of pityriasis rosea, 5 (83%) were associated with the BNT162b2 vaccine. Similarly, varicella zoster and herpes simplex reactivations have also been reported with COVID-19 infection cases and after COVID-19 vaccinations (see Table 3). Rarer reactions include a flare of previously well-controlled lichen planus, as well as petechial and purpuric rash, the latter of which has been associated with thrombocytopenia after the mRNA-1273 vaccine.

### SUMMARY

As of April 2021, more than 1 billion COVID-19 vaccine doses have been administered worldwide. Although these vaccines are instrumental against the pandemic, important knowledge gaps remain, such as our understanding of the mechanistic relationship between these vaccines and their associated cutaneous side effects.

Currently, no reactive dermatoses have been recorded outside of trial data for vaccines other than BNT162b2 and mRNA-1273. However, the COVID-19 vaccine frontier is evolving rapidly. We have summarized the latest clinical trial data for authorized COVID-19 vaccines as of April 15, 2021, and described the associated cutaneous manifestations reported in nontrial literature. Recognition of these common and emerging reactions has key implications for vaccine strategy because concerns about reactogenicity can significantly influence an individual’s willingness to return for a second dose. Because the benefits of immunization far outweigh the risks, it is crucial for health care providers, particularly dermatologists, to recognize our role in encouraging vaccine completion, educating our patients, and allaying their fears.

### CLINICS CARE POINTS

- The most common cutaneous manifestations of COVID-19 vaccination in clinical trials were local injection site reactions, of which there is a higher incidence in individuals younger than 60 years.
- The most common cutaneous manifestation of COVID-19 vaccination in real-world settings is delayed large local reactions, of which two-thirds were associated with the mRNA-1273 vaccine and one-third was associated with the BNT162b2 vaccine.
- Other reactive dermatoses to COVID-19 vaccines in real-world settings include morbilliform rashes, urticaria, erythema multiforme, delayed inflammatory reactions to dermal fillers, erythromelalgia, lichen planus, varicella zoster, herpes simplex, pityriasis rosea, petechiae, purpura. Most are self-limiting and resolve with topical steroids or oral medications.
ACKNOWLEDGEMENTS

The International League of Dermatologic Societies (ILDS) provides grant support to Massachusetts General Hospital for the AAD/ILDS COVID-19 Dermatology Registry. AAD provides in-kind support.

DISCLOSURE

Dr. Freeman is the Principal Investigator of the AAD/ILDS COVID-19 Dermatology Registry. The authors have nothing to disclose.

REFERENCES

1. WHO Coronavirus (COVID-19) Dashboard.
2. Tregoning JS, Brown ES, Cheeseman HM, et al. Vaccines for COVID-19. Clin Exp Immunol 2020;202:162–92.
3. Ledford H, Cyranoski D, Van Noorden R. The UK has approved a COVID vaccine - here’s what scientists now want to know. Nature 2020;588:205–6.
4. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021;85(1):46–55.
5. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Engl J Med 2020;384:403–16.
6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.
7. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CoV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021;21:39–51.
8. Fink AL, Klein SL. The evolution of greater humoral immunity in females than males: implications for vaccine efficacy. Curr Opin Physiol 2015;30:408–16.
9. Fischinger S, Boudreau CM, Butler AL, et al. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol 2019;41:239–49.
10. Flanagan KL, Fink AL, Plebanski M, et al. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol 2017;33:577–99.
11. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vected COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396:479–88.
12. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infect Dis 2021;21:181–92.
13. Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infect Dis 2021.
14. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111.
15. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016;16:626–38.
16. Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiol (Bethesda) 2015;30:408–16.
17. Fischinger S, Boudreau CM, Butler AL, et al. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol 2019;41:239–49.
18. Flanagan KL, Fink AL, Plebanski M, et al. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol 2017;33:577–99.
19. Blumenthal KG, Freeman EE, Saff RR, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. New Engl J Med 2021;384:1273–7.
20. Ramos CL, Kelso JM. "COVID Arm": very delayed large injection site reactions to mRNA COVID-19
vaccines. J Allergy Clin Immunol Pract 2021;9(6):2480–1.
28. CDC COVID-19 Response Team, FDA. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep 2021;70(2):46–51.
29. Ackerman M, Henry D, Finon A, et al. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(7):423-5.
30. Jedlowski PM, Jedlowski MF. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine. Dermatol Online J 2021;27.
31. Almutairi M, Azizalrahman A. Febrile morbilliform rash as a clinical presentation of COVID-19 in a pediatric patient 2020.
32. Avellana Moreno R, Estela Villa LM, Avellana Moreno V, et al. Cutaneous manifestation of COVID-19 in images: a case report. J Eur Acad Dermatol Venereol: JEADV 2020;34:e307–9.
33. Kulkarni RB, Lederman Y, Afari A, et al. Morbilliform rash: an uncommon herald of SARS-CoV-2. Cureus 2020;12:e9321.
34. Najarian DJ. Morbilliform exanthem associated with COVID-19. JAAD Case Rep 2020;6:493–4.
35. Fattori A, Cribier B, Chenard M-P, et al. Cutaneous manifestations in patients with coronavirus disease 2019: clinical and histological findings. Hum Pathol 2021;107:39–45.
36. McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. The J Allergy Clin Immunol 2018;141:463–72.
37. Centers for Disease C. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States 2021.
38. Park HJ, Montgomery JR, Boggs NA. Anaphylaxis after the Covid-19 vaccine in a patient with cholinergic urticaria. Mil Med 2021.
39. Munavalli GG, Guthridge R, Knutsen-Larson S, et al. COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment. Arch Dermatol Res 2021;1–15.
40. Munavalli GG, Knutsen-Larson S, Lupo MP, et al. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination—a model for inhibition of angiotensin II-induced cutaneous inflammation. JAAD Case Rep 2021;10:63–8.
41. Rowland-Warmann M. Hypersensitivity reaction to hyaluronic acid dermal filler following novel coronavirus infection – a case report. J Cosmet Dermatol 2021;20:1557–62.
42. Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol 2020;83:486–92.
43. Freeman EE, McMahon DE, Fox LP. Emerging evidence of the direct association between COVID-19 and chilblains. JAMA Dermatol 2021;157:238–9.
44. Lopez S, Vakharia P, Vandergriff T, et al. Pernio after COVID-19 Vaccination. Br J Dermatol 2021.
45. Kha C, Itkin A. New-onset chilblains in close temporal association to mRNA-1273 (Moderna) vaccination. JAAD case Rep 2021. https://doi.org/10.1016/j.jdcr.2021.1003.1046.
46. Hervé C, Laupèze B, Del Giudice G, et al. The how’s and what’s of vaccine reactogenicity. NPJ Vaccin 2019;4:39.
47. Busto-Leis J, Servera-Negre G, Mayor-Ibarguren A, et al. “Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance”. Journal of the European Academy of Dermatology and Venereology. n/a.
48. Malayala SV, Mohan G, Vasireddy D, et al. Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine. Cureus 2021;13:e14099.
49. Hannah Ritchie EO-O, Beletician D, Mathieu E, et al. Coronavirus (COVID-19) vaccinations. Online: our World in data 2021.